Biocryst Pharmaceuticals Inc (BCRX)

4.39
NASDAQ : Health Care
Prev Close 4.39
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.63 / 14.00
Avg Volume 954.50K
Exchange NASDAQ
Shares Outstanding 73.70M
Market Cap 341.97M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

8 Stocks Under $10 to Trade for Huge Profits

8 Stocks Under $10 to Trade for Huge Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits

Short Interest Falls 12% For BCRX

Short Interest Falls 12% For BCRX

The most recent short interest data has been released for the 06/15/2016 settlement date, which shows a 750,347 share decrease in total short interest for BioCryst Pharmaceuticals, Inc. , to 5,528,343, a decrease of 11.95% since 05/31/2016.

Biocryst Pharmaceuticals (BCRX) Is Today's Strong On High Volume Stock

Biocryst Pharmaceuticals (BCRX) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a strong on high relative volume candidate

Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a weak on high relative volume candidate

Biocryst Pharmaceuticals (BCRX) Stock: Weak On High Volume Today

Biocryst Pharmaceuticals (BCRX) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a weak on high relative volume candidate

Commit To Purchase BioCryst Pharmaceuticals At $2, Earn 18.6% Annualized Using Options

Commit To Purchase BioCryst Pharmaceuticals At $2, Earn 18.6% Annualized Using Options

Investors considering a purchase of BioCryst Pharmaceuticals, Inc. shares, but cautious about paying the going market price of $3.35/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Strong On High Volume: Biocryst Pharmaceuticals (BCRX)

Strong On High Volume: Biocryst Pharmaceuticals (BCRX)

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a strong on high relative volume candidate

7 Stocks Under $10 Making Big Moves

7 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

These 5 Biotech Stocks Under $10 Are About to Break Out

These 5 Biotech Stocks Under $10 Are About to Break Out

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Valeant Stock Plunge Puts Focus on Chairman

Robert Ingram sits on four public company boards and is a director at three private companies, which governance experts view as cause for concern.

Valeant Stock Plunge Puts Focus on Chairman Ingram and His Many Hats

Valeant Stock Plunge Puts Focus on Chairman Ingram and His Many Hats

Robert Ingram sits on four public company boards and is a director at three private companies, which governance experts view as cause for concern.

Biocryst Pharmaceuticals (BCRX) Stock: Weak On High Volume Today

Biocryst Pharmaceuticals (BCRX) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a weak on high relative volume candidate

Here's Why BioCryst Pharmaceuticals (BCRX) Stock is Spiking Today

Here's Why BioCryst Pharmaceuticals (BCRX) Stock is Spiking Today

BioCryst Pharmaceuticals (BCRX) stock is soaring on Monday afternoon after the company’s Zika drug showed promising results in mice.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks are ready to break out and trade higher from current levels.

BioCryst (BCRX) Stock Downgraded at Jefferies

BioCryst (BCRX) Stock Downgraded at Jefferies

Jefferies downgraded BioCryst (BCRX) stock and slashed its price target after the company announced disappointing trial results yesterday.

BioCryst (BCRX) Stock Plummets on Disappointing Trial Results

BioCryst (BCRX) Stock Plummets on Disappointing Trial Results

BioCryst (BCRX) stock is sinking on heavy trading volume on Monday after the company reported disappointing trial results for its treatment for angioedema attacks.

Investors Flee Risky Equities for Save-Haven Gold

Investors Flee Risky Equities for Save-Haven Gold

Stocks continue their sell off mid-afternoon Monday with investors finding little reason to jump back into equities as the risks over oil and earnings persisted.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of BioCryst Pharmaceuticals, Inc. -- BCRX

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By The Board Of BioCryst Pharmaceuticals, Inc. -- BCRX

Levi & Korsinsky announces it has commenced an investigation of BioCryst Pharmaceuticals, Inc.